GS-002 Safety and efficacy of inebilizumab in IgG4 related disease in participants with pancreatic, biliary, and hepatic involvement: results from the phase 3 MITIGATE trial

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-01 DOI:10.1016/S0168-8278(25)00299-5

Emma Culver, John Stone, Arezou Khosroshahi, Wen Zhang, Nicolas Schleinitz, Kazuichi Okazaki, Yoshiya Tanaka, Matthias Lohr, Qian Huang, Xinxin Dong, Melissa Rosen, Sue Cheng, Daniel Cimbora

引用次数: 0

查看原文本刊更多论文

inebilizumab治疗胰腺、胆道和肝脏受累患者IgG4相关疾病的安全性和有效性：来自3期缓解试验的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.